Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2611 to 2625 of 8908 results

  1. Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732 ]

    In development Reference number: GID-TA11959 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 19 February 2026.

    Interventional procedures guidance
    In consultation

  3. Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]

    In development Reference number: GID-TA11733 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  4. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  5. Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]

    In development Reference number: GID-TA11749 Expected publication date:  10 June 2027

    Technology appraisal guidance
    In development

  6. Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496]

    In development Reference number: GID-TA11676 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]

    In development Reference number: GID-TA11859 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development Reference number: GID-HTG10170 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  9. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    In development Reference number: GID-TA11643 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 6 March 2026.

    Technology appraisal guidance
    In consultation

  11. Selinexor + pomalidomide + dexamethasone for Multiple myeloma [TSID12333]

    Awaiting development Reference number: GID-TA11938 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. SEEG-guided radiofrequency thermocoagulation in refractory epilepsy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. Lumella Pre-Eclampsia Test (MT687)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  14. Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657]

    Awaiting development Reference number: GID-TA11872 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development Reference number: GID-TA11424 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development